CoChat
Sign Up
Cited by 356Cardiovascular, Neuropeptides, and Oxidative Stress ResearchElectrolyte and hormonal disordersHemodynamic Monitoring and Therapy

Science review: Vasopressin and the cardiovascular system part 1--receptor physiology.

Open access
Cheryl Lynn Holmes, Donald W. Landry, John T Granton·2003·Critical Care
DOI 10.1186/cc2337PMC PMC374366
Open this paper in CoChat — free accountOpen PDF

Abstract

Vasopressin is emerging as a rational therapy for vasodilatory shock states. Unlike other vasoconstrictor agents, vasopressin also has vasodilatory properties. The goal of the present review is to explore the vascular actions of vasopressin. In part 1 of the review we discuss structure, signaling pathways, and tissue distributions of the classic vasopressin receptors, namely V1 vascular, V2 renal, V3 pituitary and oxytocin receptors, and the P2 class of purinoreceptors. Knowledge of the function and distribution of vasopressin receptors is key to understanding the seemingly contradictory actions of vasopressin on the vascular system. In part 2 of the review we discuss the effects of vasopressin on vascular smooth muscle and the heart, and we summarize clinical studies of vasopressin in shock states.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/cc2337

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 91

  1. Hoyle CH Neuropeptide families and their receptors: evolutionary perspectives Brain Res 1999 848 1 25 10612694
  2. Acher R Chauvet J Chauvet MT Man and the chimaera. Selective versus neutral oxytocin evolution Adv Exp Med Biol 1995 395 615 627 8714026
  3. Oliver H Schaefer EA On the physiological action of extracts of the pituitary body and certain other glandular organs J Physiol (Lond) 1895 18 277 279 PMC1514634 16992253
  4. Verney EB The antidiuretic hormone and the factor which determines its release Proc R Soc Lond (Biol) 1947 135 25 106 18918876
  5. Turner RA Pierce JG Du Vigneaud V The purification and the amino acid content of vasopressin preparation J Biol Chem 1951 191 21 14850440
  6. Arnauld E Czernichow P Fumoux F Vincent JD The effects of hypotension and hypovolaemia on the liberation of vasopressin during haemorrhage in the unanaesthetized monkey (Macaca mulatta) Pflugers Arch Eur J Physiol 1977 371 193 200 414200
  7. Cowley AW Jr Switzer SJ Guinn MM Evidence and quantification of the vasopressin arterial pressure control system in the dog Circ Res 1980 46 58 67 7349918
  8. Wilson MF Brackett DJ Hinshaw LB Tompkins P Archer LT Benjamin BA Vasopressin release during sepsis and septic shock in baboons and dogs Surg Gynecol Obstet 1981 153 869 872 7029759
  9. Wilson MF Brackett DJ Release of vasoactive hormones and circulatory changes in shock Circ Shock 1983 11 225 234 6360411
  10. Wang BC Flora-Ginter G Leadley RJ Jr Goetz KL Ventricular receptors stimulate vasopressin release during hemorrhage Am J Physiol 1988 254 R204 R211 3278626
  11. Schwartz J Reid IA Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs Endocrinology 1981 109 1778 1780 7028466
  12. Abboud FM Floras JS Aylward PE Guo GB Gupta BN Schmid PG Role of vasopressin in cardiovascular and blood pressure regulation Blood Vessels 1990 27 106 115 2242439
  13. Errington ML Rocha e Silva M Jr The secretion and clearance of vasopressin during the development of irreversible haemorrhagic shock J Physiol (Lond) 1971 217 43P 45P 5571938
  14. Landry DW Levin HR Gallant EM Seo S D'Alessandro D Oz MC Oliver JA Vasopressin pressor hypersensitivity in vasodilatory septic shock Crit Care Med 1997 25 1279 1282 9267938
  15. Landry DW Levin HR Gallant EM Ashton RC Jr Seo S D'A-lessandro D Oz MC Oliver JA Vasopressin deficiency contributes to the vasodilation of septic shock Circulation 1997 95 1122 1125 9054839
  16. Morales D Madigan J Cullinane S Chen J Heath M Oz M Oliver JA Landry DW Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock Circulation 1999 100 226 229 10411844
  17. Landry DW Oliver JA The pathogenesis of vasodilatory shock N Engl J Med 2001 345 588 595 11529214
  18. Sharshar T Carlier R Blanchard A Feydy A Gray F Paillard M Raphael JC Gajdos P Annane D Depletion of neurohypophyseal content of vasopressin in septic shock Crit Care Med 2002 30 497 500 11990905
  19. Bichet DG Razi M Lonergan M Arthus MF Papukna V Kortas C Barjon JN Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus N Engl J Med 1988 318 881 887 2965301
  20. Walker BR Haynes J Jr Wang HL Voelkel NF Vasopressin-induced pulmonary vasodilation in rats Am J Physiol 1989 257 H415 H422 2764128
  21. Evora PR Pearson PJ Schaff HV Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide Chest 1993 103 1241 1245 8131474
  22. Suzuki Y Satoh S Oyama H Takayasu M Shibuya M Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo Stroke 1993 24 1049 1053 7686696
  23. Rudichenko VM Beierwaltes WH Arginine vasopressin-induced renal vasodilation mediated by nitric oxide J Vasc Res 1995 32 100 105 7734655
  24. Tamaki T Kiyomoto K He H Tomohiro A Nishiyama A Aki Y Kimura S Abe Y Vasodilation induced by vasopressin V2 receptor stimulation in afferent arterioles Kidney Int 1996 49 722 729 8648913
  25. Okamura T Toda M Ayajiki K Toda N Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries J Vasc Res 1997 34 464 472 9425999
  26. Okamura T Ayajiki K Fujioka H Toda N Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries J Hypertens 1999 17 673 678 10403611
  27. Barberis C Mouillac B Durroux T Structural bases of vasopressin/oxytocin receptor function J Endocrinol 1998 156 223 229 9518866
  28. Swaab DF Nijveldt F Pool CW Distribution of oxytocin and vasopressin in the rat supraoptic and paraventricular nucleus J Endocrinol 1975 67 461 462 1206330
  29. Riddell DC Mallonee R Phillips JA Parks JS Sexton LA Hamerton JL Chromosomal assignment of human sequences encoding arginine vasopressin-neurophysin II and growth hormone releasing factor Somat Cell Mol Genet 1985 11 189 195 2984790
  30. Summar ML Phillips JA III Battey J Castiglione CM Kidd KK Maness KJ Weiffenbach B Gravius TC Linkage relationships of human arginine vasopressin-neurophysin-II and oxytocin-neurophysin-I to prodynorphin and other loci on chromosome 20 Mol Endocrinol 1990 4 947 950 1978246
  31. Ruppert S Scherer G Schutz G Recent gene conversion involving bovine vasopressin and oxytocin precursor genes suggested by nucleotide sequence Nature 1984 308 554 557 6709064
  32. Burbach J Regulation of gene promoters of hypothalamic peptides Front Neuroendocrinol 2002 23 342 369 12381330
  33. Thibonnier M Conarty DM Preston JA Wilkins PL Berti-Mattera LN Mattera R Molecular pharmacology of human vasopressin receptors Adv Exp Med Biol 1998 449 251 276 10026814
  34. Zenteno-Savin T Sada-Ovalle I Ceballos G Rubio R Effects of arginine vasopressin in the heart are mediated by specific intravascular endothelial receptors Eur J Pharmacol 2000 410 15 23 11134652
  35. Neves SR Ram PT Iyengar R G protein pathways Science 2002 296 1636 1639 12040175
  36. Berrada K Plesnicher CL Luo X Thibonnier M Dynamic interaction of human vasopressin/oxytocin receptor subtypes with g protein-coupled receptor kinases and protein kinase c after agonist stimulation J Biol Chem 2000 275 27229 27237 10858434
  37. Ross EM Gilman AG Biochemical properties of hormone-sensitive adenylate cyclase Annu Rev Biochem 1980 49 533 564 6105841
  38. Birnbaumer M Mutations and diseases of G protein coupled receptors J Recept Signal Transduct Res 1995 15 131 160 8903937
  39. Zhu X Gilbert S Birnbaumer M Birnbaumer L Dual signaling potential is common among Gs-coupled receptors and dependent on receptor density Mol Pharmacol 1994 46 460 469 7935326
  40. Klein U Muller C Chu P Birnbaumer M von Zastrow M Heterologous inhibition of G protein-coupled receptor endocytosis mediated by receptor-specific trafficking of beta-arrestins J Biol Chem 2001 276 17442 17447 11278476
  41. Shi CS Kehrl JH PYK2 links G(q)alpha and G(13)alpha signaling to NF-kappa B activation J Biol Chem 2001 276 31845 31850 11435419
  42. Thibonnier M Graves MK Wagner MS Auzan C Clauser E Willard HF Structure, sequence, expression, and chromosomal localization of the human V1a vasopressin receptor gene Genomics 1996 31 327 334 8838314
  43. Briley EM Lolait SJ Axelrod J Felder CC The cloned vasopressin V1a receptor stimulates phospholipase A2, phospholipase C, and phospholipase D through activation of receptor-operated calcium channels Neuropeptides 1994 27 63 74 7969820
  44. Filep J Rosenkranz B Mechanism of vasopressin-induced platelet aggregation Thromb Res 1987 45 7 15 3105115
  45. Vittet D Launay JM Chevillard C Homologous regulation of human platelet vasopressin receptors does not occur in vivo Am J Physiol 1989 257 R1400 R1405 2532481
  46. Lachant NA Smith MR Xie ZJ Romani WR Heterogeneity of the aggregation response of human platelets to arginine vasopressin Am J Hematol 1995 49 56 66 7741139
  47. Cottet-Maire F Avdonin PV Roulet E Buetler TM Mermod N Ruegg UT Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin A treatment Br J Pharmacol 2001 132 909 917 11181432 PMC1572618
  48. Lo Russo A Passaquin AC Ruegg UT Mechanism of enhanced vasoconstrictor hormone action in vascular smooth muscle cells by cyclosporin A Br J Pharmacol 1997 121 248 252 9154334 PMC1564667
  49. Edwards RM Trizna W Kinter LB Renal microvascular effects of vasopressin and vasopressin antagonists Am J Physiol 1989 256 F274 F278 2916660
  50. Holmes CL Walley KR Chittock DR Lehman T Russell JA The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series Intensive Care Med 2001 27 1416 1421 11511958
  51. Innamorati G Sadeghi H Birnbaumer M A fully active nonglycosylated V2 vasopressin receptor Mol Pharmacol 1996 50 467 473 8794883
  52. Erlenbach I Wess J Molecular basis of V2 vasopressin receptor/Gs coupling selectivity J Biol Chem 1998 273 26549 26558 9756892
  53. Liu J Wess J Different single receptor domains determine the distinct G protein coupling profiles of members of the vasopressin receptor family J Biol Chem 1996 271 8772 8778 8621513
  54. Birnbaumer M Vasopressin receptors Trends Endocrinol Metab 2000 11 406 410 11091117
  55. Orloff J Handler J The role of adenosine 3',5'-phosphate in the action of antidiuretic hormone Am J Med 1967 42 757 768 5337377
  56. Dousa TP Walter R Schwartz IL Sands H Hechter O Role of cyclic AMP in the action of neurohypophyseal hormones on kidney Adv Cyclic Nucleotide Res 1972 1 121 135 4353162
  57. Harris HW Jr Zeidel ML Jo I Hammond TG Characterization of purified endosomes containing the antidiuretic hormone-sensitive water channel from rat renal papilla J Biol Chem 1994 269 11993 12000 8163502
  58. Knepper MA Inoue T Regulation of aquaporin-2 water channel trafficking by vasopressin Curr Opin Cell Biol 1997 9 560 564 9261056
  59. Kambouris M Dlouhy SR Trofatter JA Conneally PM Hodes ME Localization of the gene for X-linked nephrogenic diabetes insipidus to Xq28 Am J Med Genet 1988 29 239 246 2894172
  60. Rosenthal W Antaramian A Gilbert S Birnbaumer M Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase J Biol Chem 1993 268 13030 13033 8514744
  61. Rousseau-Merck MF Rene P Derre J Bienvenu T Berger R de Keyzer Y Chromosomal localization of the human V3 pituitary vasopressin receptor gene (AVPR3) to 1q32 Genomics 1995 30 405 406 8586456
  62. Sugimoto T Saito M Mochizuki S Watanabe Y Hashimoto S Kawashima H Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor J Biol Chem 1994 269 27088 27092 7929452
  63. Thibonnier M Preston JA Dulin N Wilkins PL Berti-Mattera LN Mattera R The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways Endocrinology 1997 138 4109 4122 9322919
  64. Thibonnier M Berti-Mattera LN Dulin N Conarty DM Mattera R Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors Prog Brain Res 1998 119 147 161 10074787
  65. Liu JP Engler D Funder JW Robinson PJ Arginine vasopressin (AVP) causes the reversible phosphorylation of the myristoylated alanine-rich C kinase substrate (MARCKS) protein in the ovine anterior pituitary: evidence that MARCKS phosphorylation is associated with adrenocorticotropin (ACTH) secretion Mol Cell Endocrinol 1994 101 247 256 9397959
  66. Lee B Yang C Chen TH al-Azawi N Hsu WH Effect of AVP and oxytocin on insulin release: involvement of V1b receptors Am J Physiol 1995 269 E1095 E1100 8572202
  67. Peter J Burbach H Adan RA Lolait SJ van Leeuwen FW Mezey E Palkovits M Barberis C Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family Cell Mol Neurobiol 1995 15 573 595 8719042 PMC11563090
  68. Gimpl G Fahrenholz F The oxytocin receptor system: structure, function, and regulation Physiol Rev 2001 81 629 683 11274341
  69. Sanborn BM Dodge K Monga M Qian A Wang W Yue C Molecular mechanisms regulating the effects of oxytocin on myometrial intracellular calcium Adv Exp Med Biol 1998 449 277 286 10026815
  70. Thibonnier M Conarty DM Preston JA Plesnicher CL Dweik RA Erzurum SC Human vascular endothelial cells express oxytocin receptors Endocrinology 1999 140 1301 1309 10067857
  71. Gutkowska J Jankowski M Lambert C Mukaddam-Daher S Zingg HH McCann SM Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart Proc Natl Acad Sci USA 1997 94 11704 11709 9326674 PMC23602
  72. Paquin J Danalache BA Jankowski M McCann SM Gutkowska J Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes Proc Natl Acad Sci USA 2002 99 9550 9555 12093924 PMC123178
  73. Boarder MR Weisman GA Turner JT Wilkinson GF G protein-coupled P2 purinoceptors: from molecular biology to functional responses Trends Pharmacol Sci 1995 16 133 139 7610499
  74. Mei Q Liang BT P2 purinergic receptor activation enhances cardiac contractility in isolated rat and mouse hearts Am J Physiol Heart Circ Physiol 2001 281 H334 H341 11406501
  75. Zheng JS Christie A De Young MB Levy MN Scarpa A Synergism between cAMP and ATP in signal transduction in cardiac myocytes Am J Physiol 1992 262 C128 C135 1310205
  76. Diaz Brinton R Brownson EA Vasopressin-induction of cyclic AMP in cultured hippocampal neurons Brain Res Dev Brain Res 1993 71 101 105 8381727
  77. de Wied D Elands J Kovacs G Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior: mediation by a cerebral neurohypophyseal hormone receptor? Proc Natl Acad Sci USA 1991 88 1494 1498 1847526 PMC51045
  78. Freedman NJ Lefkowitz RJ Desensitization of G protein-coupled receptors Recent Prog Horm Res 1996 51 319 351 8701085
  79. Chuang TT Iacovelli L Sallese M De Blasi A G protein-coupled receptors: heterologous regulation of homologous desensitization and its implications Trends Pharmacol Sci 1996 17 416 421 8990958
  80. Perry SJ Baillie GS Kohout TA McPhee I Magiera MM Ang KL Miller WE McLean AJ Conti M Houslay MD Lefkowitz RJ Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins Science 2002 298 834 836 12399592
  81. Zhang M Turnbaugh D Cofie D Dogan S Koshida H Fugate R Kem DC Protein kinase C modulation of cardiomyocyte angiotensin II and vasopressin receptor desensitization Hypertension 1996 27 269 275 8567051
  82. Oakley RH Laporte SA Holt JA Barak LS Caron MG Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization J Biol Chem 1999 274 32248 32257 10542263
  83. Innamorati G Sadeghi H Birnbaumer M Phosphorylation and recycling kinetics of G protein-coupled receptors J Recept Signal Transduct Res 1999 19 315 326 10071767
  84. Karmazyn M Manku MS Horrobin DF Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins Endocrinology 1978 102 1230 1236 744021
  85. Noguera I Medina P Segarra G Martinez MC Aldasoro M Vila JM Lluch S Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery Br J Pharmacol 1997 122 431 438 9351498 PMC1564956
  86. Laugwitz KL Ungerer M Schoneberg T Weig HJ Kronsbein K Moretti A Hoffmann K Seyfarth M Schultz G Schomig A Adenoviral gene transfer of the human V2 vasopressin receptor improves contractile force of rat cardiomyocytes Circulation 1999 99 925 933 10027817
  87. Hibert M Hoflack J Trumpp-Kallmeyer S Mouillac B Chini B Mahe E Cotte N Jard S Manning M Barberis C Functional architecture of vasopressin/oxytocin receptors J Recept Signal Transduct Res 1999 19 589 596 10071787
  88. Bankowski K Manning M Haldar J Sawyer WH Design of potent antagonists of the vasopressor response to argininevasopressin J Med Chem 1978 21 850 853 722751
  89. Manning MSWH Discovery, development, and some uses of vasopressin and oxytocin antagonists J Lab Clin Med 1989 114 617 632 2687422
  90. Holmes CL Patel BM Russell JA Walley KR Physiology of vasopressin relevant to management of septic shock Chest 2001 120 989 1002 11555538
  91. Thibonnier M Coles P Thibonnier A Shoham M Molecular pharmacology and modeling of vasopressin receptors Prog Brain Res 2002 139 179 196 12436935

Cited by

Sorted by citations

Authors
Holmes, C. L., Landry, D. W., & Granton, J. T.
Affiliations
  • University of Toronto (CA)
  • Columbia University (US)
  • University Health Network (CA)
Corresponding author
John T Granton
ORCID
Venue
Critical Care
Publisher
Springer Science and Business Media LLC
Published
2003
Volume
7
Issue
6
Pages
427
ISSN
1364-8535 (ISSN-L)
DOI
10.1186/cc2337
PMC
PMC374366
OpenAlex
W2165073682
Cited by
356
References
2
Citations by year
2026: 7 · 2025: 15 · 2024: 6 · 2023: 17 · 2022: 12 · 2021: 14 · 2020: 15 · 2019: 12 · 2018: 11 · 2017: 18 · 2016: 22 · 2015: 21 · 2014: 25 · 2013: 17 · 2012: 13
FWCI
1.33
Type
journal article
Language
en
Open access
Locations
  • Critical Care (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Cardiovascular, Neuropeptides, and Oxidative Stress Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Electrolyte and hormonal disorders
  • Health Sciences › Medicine › Surgery › Hemodynamic Monitoring and Therapy
Keywords
vasopressin, vasopressin receptor, V1 receptor, V2 receptor, oxytocin receptor, purinergic receptors, purinergic signaling, vasodilatory shock, vasopressin therapy, vascular smooth muscle, receptor signaling pathways
MeSH terms
Humans, Muscle, Smooth, Vascular, Vasopressins, Signal Transduction, Receptors, Vasopressin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review